Review anchor
Sodium channel protein type 9 subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Sodium channel protein type 9 subunit alpha
CHEMBL4296
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium channel protein type 9 subunit alpha as ChEMBL target CHEMBL4296, mapped to UniProt Q15858. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4296
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q15858
Sodium channel protein type 9 subunit alpha
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Sodium channel protein type 9 subunit alpha matters
Sodium channel protein type 9 subunit alpha is reviewed as Sodium channel protein type 9 subunit alpha (UniProt Q15858); Sodium channel protein type 9 subunit alpha shows late clinical disease relevance led by trigeminal neuralgia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 14 approved drugs, 8714 compounds, and 390 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Sodium channel protein type 9 subunit alpha
Sodium channel protein type 9 subunit alpha Sequence length is 1988 aa.
Review this target as Sodium channel protein type 9 subunit alpha, mapped to UniProt Q15858. Sequence length is 1988 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q15858
Protein
Disease context
trigeminal neuralgia
Sodium channel protein type 9 subunit alpha shows late clinical disease relevance led by trigeminal neuralgia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include VIXOTRIGINE.
Start review with trigeminal neuralgia because it currently carries late clinical support. Linked drugs include VIXOTRIGINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 14 approved drugs, 8714 compounds, and 390 assays for this target. The dominant activity type is IC50. CHEMBL4217988 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL4217988 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
14 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Sodium channel protein type 9 subunit alpha matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q15858, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why trigeminal neuralgia is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
8714
Total Compounds
390
Total Assays
14
Approved Drugs
IC50: 10537.0, KI: 246.0, EC50: 7.0, KD: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4217988
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL1224266
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL3318148
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL4205773
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL4210135
|
10.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LACOSAMIDE
CHEMBL58323
|
2008 |
|
|
TETRACAINE
CHEMBL698
|
2005 |
|
|
MIBEFRADIL
CHEMBL45816
|
1997 |
|
|
AMITRIPTYLINE
CHEMBL629
|
1961 |
Source Header